<DOC>
	<DOCNO>NCT01160952</DOCNO>
	<brief_summary>- The primary objective study evaluate efficacy safety profile itraconazole primary prophylaxis - The second objective study find difference long-term versus short-term sequential therapy Itraconazole ( intravenous follow oral itraconazole ) primary prophylaxis invasive fungal infection ( IFI ) patient undergo allogeneic stem cell transplantation ( allo-SCT ) - also explore relationship incidence IFI plasma concentration itraconazole hydroxy-itraconazole</brief_summary>
	<brief_title>Long-term Versus Short-term Sequential Therapy ( Intravenous Itraconazole Followed Oral Solution ) Itraconazole Primary Prophylaxis Patients Undergoing Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Invasive fungal infection ( IFI ) remain major cause death among neutropenic patient receive high dose chemotherapy allo-SCT . Especially , patient undergo allo-SCT generally receive intensive immunosuppressive therapy , make patient high risk develop IFI . Prompt intensive antifungal therapy may increase incidence rate IFI improve response survival . Antifungal prophylaxis recommend patient undergo allo-SCT Infectious disease society America ( IDSA ) Chinese guideline diagnosis management IFI patient hematologic/malignant tumor ( revise ) . Few study address role previous IFI feasibility stem cell transplant , secondary prophylaxis antifungal drug prevent recurrence infection transplantation . However , give lack prospective study , role primary antifungal prevention course treatment remain unclear . Itraconazole wide-spectrum triazole antifungal agent active Candida albicans , non-albicans , Aspergillus spp. , Blastomyces dermatitidis , Blastomyces coccidioides , Cryptococcus neoformans , Sporothrix schenkii , Paracoccidioides brasiliensis , Histoplasma spp . various kind yeast fungi mycetes . The role itraconazole IFI prophylaxis prove many interventional study . However optimal course prophylaxis still unknown，especially China . In prospective , multicentric study primary antifungal prevention , long-term short-term sequential therapy ( intravenous follow oral itraconazole ) give standard dose patient undergo allogeneic stem cell transplantation ass efficacy safety itraconazole primary prophylaxis , analysis relationship incidence rate IFI plasma concentration itraconazole hydroxy-itraconazole .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Man woman 14 60 year age , inclusive Patients affect hematological disease , receive alloSCT Patients previous proven probable invasive fungal infection . Patients without microbiological evidence effective antifungal therapy history inclusive Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Currently take contraindicated medication teldane , astemizol , cisapride HMGCoA reductase inhibitor（e.g . Simvastatin , lovastatin , oral Midazolam Triazolam） History allergy intolerance imidazole azoles antifungal agent ( e.g . Fluconazol , Itraconazole , Ketoconazole , Miconazole , Clotrimazole ) Pregnant woman , lactate woman woman child bear potential without apply valid contraceptive measure Patients current cardiac dysfunction ( especially congestive heart failure ) history congestive heart failure Patients severe liver dysfunction ( aminotransferase level &gt; = 5 time upper limit normal total bilirubin level &gt; = 3mg/dL ( 51.3 μmol/L ) ; severity liver dysfunction match criterion patient bad condition suitable trial ( doctor make decision ) ; Patients renal insufficiency serum Ccr level &lt; 30ml/min , calculate follow formula : Male : Ccr ( ml/min ) = ( 140age ) ×weight ( kg ) / ( 0.8136×Crea ( μmol/L ) ) Female : Ccr ( ml/min ) = ( 140age ) ×weight ( kg ) ×0.85/ ( 0.8136× Crea ( μmol/L ) ) Patients receive experimental drug within 14 day plan start treatment . Patients bad whole body status suitable trial ( doctor make decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>primary prophylaxis</keyword>
	<keyword>itraconazole</keyword>
	<keyword>stem cell transplantation</keyword>
</DOC>